InDex Pharmaceuticals Holding AB (publ) (INDEX.ST)
InDex Pharmaceuticals Holding AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Solna, SE. The stock last traded at $0.56, up 3.72% on the session, giving a market capitalisation of $3.69B. Its beta of -0.21 implies it has historically moved less than the broad market.
InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to developing therapeutic solutions for patients affected by ulcerative colitis. The company's flagship drug candidate, Cobitolimod, is presently in Phase III clinical trials, targeting the treatment of moderate to severe ulcerative colitis. Furthermore, InDex is progressing a pipeline of other DNA-based immunomodulatory sequences, which are in the preclinical phase, designed to address various immunological conditions. This enterprise was established in 2000 and operates from its headquarters in Solna, Sweden.
InDex Pharmaceuticals Holding AB (publ) is most often compared with the following Healthcare names: